WHO ICTRP trial
Bioequivalence study of two different Famotidine formulations
IRCT20111107008022N11 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20111107008022N11 |
|---|---|
| Public title | Bioequivalence study of two different Famotidine formulations |
| Scientific title | Comparative bioequivalence study of two different Famotidine 40 mg formulations (Zagros Darou Pharmaceutical Company & reference) in 24 Iranian volunteers |
| Primary sponsor | Zagrous Darou Pharmaceutical Company |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Health and normal volunteers. |
| Interventions | Intervention group: Single dose of Famodin 40 mg tablet manufactured by Sandoz Pharmaceutical company in 24 healthy volunteers. |
| Registration date | Mar 6, 2024 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: